NCT05279742View on ClinicalTrials.gov

Enhancing the Natriuretic Peptide System in HFpEF

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Heart Failure With Preserved Ejection FractionChronic Kidney Diseases
Interventions
DRUG

MANP

Single subcutaneous injection 5 µg/Kg

DRUG

Sacubitril/Valsartan

Oral single dose 97/103 mg

DRUG

Oral Placebo

Oral single dose that contains no active ingredient

DRUG

Injection Placebo

Single subcutaneous injection that contains no active ingredient

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

All Listed Sponsors
lead

Horng Chen

OTHER